Table 3. Site of metastatic disease recurrence based on EGFR mutation status and initial stage.

	EGFR Mutated	EGFR Wildtype	P-value
Proportion with lung-only metastasis among those with metastasis, N (%)	8 (26%)	3 (14%)	0.51
Stage 1	6 (35%)	1 (17%)	0.74
Stage 2	0 (0%)	1 (17%)	> 0.99
Stage 3	2 (17%)	1 (11%)	> 0.99
Metastatic site in those with metastasis, N (%)
Lung	18 (58%)	9 (43%)	0.43
Liver	4 (13%)	1 (5%)	0.62
Bone	6 (19%)	3 (14%)	0.92
Adrenal	1 (3%)	1 (5%)	> 0.99
Brain	8 (26%)	5 (24%)	> 0.99
Pleura	10 (32%)	2 (10%)	0.12
Soft tissue	0 (0%)	1 (5%)	0.84
Lymph node	5 (16%)	9 (43%)	0.07
Thyroid	0 (0%)	1 (5%)	0.84
Gastrointestinal tract	0 (0%)	1 (5%)	0.84
Pericardium	1 (3%)	0 (0%)	> 0.99